These blood biomarkers can predict drug efficacy or serious skin toxicity earlier than the occurrence of a skin rash, and it is more appropriate to predict the effect of EGFR inhibitors for patients who are not prone to skin toxicity. The gene discussed is EGFR; the disease is exanthem.